Salidroside Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via AMPK-Dependent TXNIP/NLRP3 Pathway

Figure 6

Salidroside (SAL) improves abnormal lipid accumulation and AMPK activity in a dose-dependent manner in hepatocytes. After cultured overnight in the serum-free medium which contains normal glucose (NG, 5.5 mM), primary mouse hepatocytes were incubated in the serum-free medium which contains 30 mM glucose and 100 nM insulin (HG) and treated with 10 μM SAL for the indicated periods of time (0–72 h), or treated with SAL (0.1, 1, 10 μM) for 72 h. The Oil Red O staining (a, d) and lipid content detection (b, e) were carried out. Protein sample was extracted from hepatocytes, and the phosphorylation of AMPK and ACC (c, f) was analyzed by immunoblot. Scale bar = 200 μm. , versus NG; , versus HG. Values are means ± s.e.m. ((a) and (d): ; (b), (c), (e), and (f): ).

(a)

(b)

(c)

(d)

(e)

(f)